Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0PJKLO
ADC Name	J80A-PE24
Synonyms	J80A PE24; J80APE24 Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Hepatocellular carcinoma [ICD11:2C12] Investigative
	3D MOL	2D MOL
Antibody Name	Anti-GPC3 mAb J80A		Antibody Info
Antigen Name	Glypican-3 (GPC3)		Antigen Info
Payload Name	Pseudomonas exotoxin PE24		Payload Info
Therapeutic Target	Eukaryotic elongation factor 2 (EEF2)		Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 83.3	%	Hepatocellular carcinoma cells	Hepatocellular carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	Hepatocellular carcinoma cells	Hepatocellular carcinoma

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Inhibitory Concentration 5% (IC5)	110	ng/mL	G1LG cells	Hepatocellular carcinoma
Half Maximal Inhibitory Concentration (IC50)	7.9	ng/mL	Hep3BLG cells	Pediatric hepatocellular carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.30% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	J80A-PE24 induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	J80A-PE24+FGF-401 induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma CDX model
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing. Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.90 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing. Click to Show/Hide
In Vitro Model	Pediatric hepatocellular carcinoma	Hep3BLG cells		Homo sapiens

References

Ref 1	Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma. J Cancer. 2022 Feb 14;13(4):1370-1384.